Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis.

ABSTRACT:

Background

With a suite of promising new RSV prophylactics on the horizon, including long-acting monoclonal antibodies and new vaccines, it is likely that one or more of these will replace the current monoclonal Palivizumab programme. However, choosing the optimal intervention programme will require balancing the costs of the programmes with the health benefits accrued.

Methods

To compare the next generation of RSV prophylactics, we integrated a novel transmission model with an economic analysis. We estimated key epidemiological parameters by calibrating the model to 7 years of historical epidemiological data using a Bayesian approach. We determined the cost-effective and affordable maximum purchase price for a comprehensive suite of intervention programmes.

Findings

SUBMITTER: Hodgson D 

PROVIDER: S-EPMC7672821 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature